Literature DB >> 25488094

Market-access agreements for anti-cancer drugs.

Katelijne van de Vooren1, Alessandro Curto1, Nick Freemantle2, Livio Garattini3.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25488094      PMCID： PMC4484207          DOI： 10.1177/0141076814559626

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  9 in total

1.  Efficacy, safety, and cost of new anticancer drugs.

Authors:  Silvio Garattini; Vittorio Bertele
Journal:  BMJ       Date:  2002-08-03

2.  Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Authors:  Louis P Garrison; Adrian Towse; Andrew Briggs; Gerard de Pouvourville; Jens Grueger; Penny E Mohr; J L Hans Severens; Paolo Siviero; Miguel Sleeper
Journal:  Value Health       Date:  2013-07-19       Impact factor: 5.725

3.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Risk sharing agreements: what lessons from Italy?

Authors:  Livio Garattini; Gianluigi Casadei
Journal:  Int J Technol Assess Health Care       Date:  2011-03-24       Impact factor: 2.188

Review 5.  Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

Authors:  Josh J Carlson; Sean D Sullivan; Louis P Garrison; Peter J Neumann; David L Veenstra
Journal:  Health Policy       Date:  2010-03-11       Impact factor: 2.980

6.  Optional copayments on anti-cancer drugs.

Authors:  Katelijne van de Vooren; Alessandro Curto; Livio Garattini
Journal:  BMJ       Date:  2013-01-24

Review 7.  Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.

Authors:  Josh J Carlson; Katharine S Gries; Kai Yeung; Sean D Sullivan; Louis P Garrison
Journal:  Appl Health Econ Health Policy       Date:  2014-06       Impact factor: 2.561

Review 8.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 9.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655
  9 in total
  10 in total

1.  Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

Authors:  Livio Garattini; Alessandro Curto; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

2.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

3.  Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions?

Authors:  Livio Garattini; Alessandro Curto
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

4.  Immunotherapies for advanced melanoma: as promising as they are expensive?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-09-05       Impact factor: 5.344

5.  Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.

Authors:  Livio Garattini; Nicholas Freemantle
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

6.  Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.

Authors:  Agnes Vitry; Barbara Mintzes; Wendy Lipworth
Journal:  J Pharm Policy Pract       Date:  2016-04-07

7.  Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.

Authors:  Kim Pauwels; Isabelle Huys; Sabine Vogler; Minne Casteels; Steven Simoens
Journal:  Front Pharmacol       Date:  2017-04-04       Impact factor: 5.810

8.  Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy.

Authors:  Panos Kefalas; Omar Ali; Jesper Jørgensen; Nick Merryfield; Tim Richardson; Adam Meads; Laura Mungapen; Matthew Durdy
Journal:  J Mark Access Health Policy       Date:  2018-08-20

9.  Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.

Authors:  Olina Efthymiadou; Panos Kanavos
Journal:  BMC Health Serv Res       Date:  2022-08-20       Impact factor: 2.908

10.  Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America.

Authors:  Daniela Moye-Holz; S Vogler
Journal:  Appl Health Econ Health Policy       Date:  2021-07-06       Impact factor: 3.686
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.